By
Donald Zuhn --
Last
month, ChemBridge Corp. announced
that it would make ten of its most popular chemical screening libraries
available to researchers via the Collaborative Drug Discovery (CDD) Public
Access database. The CDD Public
Access database, a collection of public data from leading vendors, researchers,
scientific literature, and patent resources, is hosted by Collaborative Drug
Discovery, Inc. as a service to the research community. Collaborative Drug Discovery provides
web-based software for organizing preclinical research data to help scientists
more effectively advance new drug candidates. Researchers can register for free read-only access to the
CDD public data sets here;
read-and-write access, including the ability to archive, mine, and collaborate
around private data and to import and export both private and public data is
also available. Compounds from the
ten ChemBridge libraries being added to the Public Access database can be
obtained from the San Diego-based discovery chemistry company.
The
libraries being offered by ChemBridge include its DIVERSet, a 50,000 diverse
small molecule dataset covering a broad range of pharmacophore space; and
CNS-Set, which contains 56,000 molecules with an increased probability of blood
brain barrier penetration.
ChemBridge noted that more than 600,000 molecules would be available
through the CDD database. CDD CEO
Barry Bunin stated that both the CDD community for private access and the
entire researcher community for public access would benefit from the addition
of the ten ChemBridge libraries.
Prior to the addition of the ChemBridge molecules, the CDD database
contained over a million compounds.
Comments